AUSTIN, TEXAS – October 9, 2013 – LDR Holding Corporation (NASDAQ: LDRH) (“LDR” or the “Company”), a global medical device company focused on designing and commercializing novel and proprietary spinal surgical technologies, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a price of $15.00 per share. In addition, LDR has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price to cover any over-allotments. All of the shares are being offered by LDR. The shares are expected to begin trading on The NASDAQ Stock Market on Wednesday, October 9, 2013 under the ticker symbol “LDRH”. The offering is expected to close on October 15, 2013.
Piper Jaffray & Co., William Blair & Company, L.L.C., and Bryan, Garnier & Co. are acting as joint book-running managers for the offering. Cowen and Company, JMP Securities LLC and Stephens Inc. are acting as co-managers.
A registration statement relating to the shares of LDR’s common stock has been filed with, and declared effective by, the Securities and Exchange Commission. The offering of these securities will be made only by means of a prospectus forming a part of the effective registration statement. A copy of the prospectus may be obtained from the offices of Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at email@example.com; William Blair & Company, L.L.C. at 222 West Adams Street, Chicago, IL 60606, Attention: Prospectus Department, by telephone at (800) 621-0687, or by email at firstname.lastname@example.org; or Bryan Garnier & Co. (Paris office) 26, avenue des Champs-Élysées, 75008 Paris France or by email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About LDR Holding Corporation
LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. The Company’s primary products are based on its exclusive VerteBRIDGE fusion and Mobi non-fusion technology platforms that have applications in the cervical and lumbar spine. These technologies enable products that are less invasive, provide greater intra-operative flexibility, offer simplified surgical techniques and promote improved clinical outcomes for patients as compared to existing alternatives. The Company recently received approval from the U.S. Food and Drug Administration (the “FDA”) for the Mobi-C cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. LDR was founded in Troyes, France, and is headquartered in Austin, Texas. In addition to Austin and Troyes, LDR has regional offices in Germany, Spain, China, South Korea and Brazil. For more information regarding LDR Holding, visit www.ldr.com.
Certain statements contained in this release that are not historical information contain forward-looking statements. The forward-looking statements involve risks and uncertainties and actual results may differ materially from those projected or implied. Further, certain forward-looking statements are based on assumptions of future events which may not prove to be accurate. These factors are discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections and elsewhere in the Company’s registration statement.
You should keep in mind that any forward-looking statement made by the Company herein, or elsewhere, speaks only as of the date on which made. New risks and uncertainties come up from time to time, and it is impossible for the Company to predict these events or how they may affect it. The Company has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.